Supreme Court preserves mail access to mifepristone (opens in new tab)

The U.S. Supreme Court on May 14 kept access to mifepristone through telehealth and mail in place while litigation continues, blocking a lower-court order that would have reinstated an in-person dispensing requirement nationwide. The unsigned order granted emergency requests from mifepristone manufacturers Danco Laboratories and GenBioPro; Justices Clarence Thomas and Samuel Alito dissented. The case, Louisiana v. FDA, challenges Food and Drug Administration rules allowing mifepristone to be ...